Disease models are essential for understanding cardiovascular disease pathogenesis and
developing new therapeutics. The human induced pluripotent stem cell (iPSC) technology …

Cardiovascular disease is the leading cause of death worldwide. Although investment in
drug discovery and development has been sky-rocketing, the number of approved drugs has …

Cardiac tissues generated from human induced pluripotent stem cells (iPSCs) can serve as
platforms for patient-specific studies of physiology and disease,,,,–. However, the predictive …

Existing methods for human induced pluripotent stem cell (hiPSC) cardiac differentiation are
efficient but require complex, undefined medium constituents that hinder further elucidation …

We have previously developed a high-throughput bioengineered human cardiac organoid
(hCO) platform, which provides functional contractile tissue with biological properties similar …

Current practices in drug development have led to therapeutic compounds being approved
for widespread use in humans, only to be later withdrawn due to unanticipated toxicity …

Cell therapy has been a promising strategy for cardiac repair after injury or infarction;
however, low retention and engraftment of transplanted cells limit potential therapeutic …

The prospect of changing the plasticity of terminally differentiated cells toward pluripotency
has completely altered the outlook for biomedical research. Human-induced pluripotent …

Inflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction,.
However, the molecular mechanisms driving immune–fibroblast cell communication in …

Bioelectrical impulses intrinsically generated within the sinoatrial node (SAN) trigger the
contraction of the heart in mammals. Though discovered over a century ago, the molecular …